---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063369"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:42:37.958482+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aptevo Q3 2023 net loss $6.3M; cash $19.1M; funding extends runway into Q4 2024

## Summary
- Net loss of $6.3M ($0.50 per share) vs $7.6M loss in Q3 2022; no revenue reported.
- Cash and equivalents $19.1M at Sept 30; raised $7M via public offering and warrant exercises, with potential additional $9.2M.
- R&D expenses $3.9M (down $0.6M); G&A $2.7M (down $0.6M) year-over-year.
- ALG.APV-527 Phase 1 dose-escalation trial for solid tumors continues enrolling patients; APVO436 Phase 2 planning ongoing.
- Cash runway expected into Q4 2024, allowing reach of clinical milestones.

## SEC filing metadata
- accession: 0000950170-23-063369
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/0000950170-23-063369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/apvo-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063369
- JSON: https://secwatch.observer/filing/0000950170-23-063369.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063369.txt

## Key facts
- Earnings Releases
  Aptevo Therapeutics Inc. reported the quarter ended September 30, 2023 results: net income net loss of $6.3 million or $0.50 per share, EPS $0.50 per share.
  - Period: the quarter ended September 30, 2023
  - Net income: net loss of $6.3 million or $0.50 per share
  - EPS: $0.50 per share
  - Result: reported results
  source text: Aptevo had a net loss of $6.3 million or $0.50 per share for the three months ended September 30, 2023, compared to a net loss of $7.6 million or $1.50 per share for the corresponding period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/0000950170-23-063369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.